Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TEC Finds iFOBT Test Evidence Lacking In Contrast To Medicare Decision

This article was originally published in The Gray Sheet

Executive Summary

A 1BlueCross BlueShield Association TEC assessment finding insufficient evidence on the use of immunochemical fecal occult blood tests contradicts a recent positive Medicare national coverage decision

You may also be interested in...



Immunochemical Colorectal Cancer Test An Accurate Adjunct – Lancet Study

The combination of guaiac and immunochemical fecal occult blood testing can reduce the need for colonoscopies by 30%, according to a Lancet study published Jan. 5

Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

UsernamePublicRestriction

Register

MT020781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel